Literature DB >> 31874336

Feasibility of integrating computer-aided diagnosis with structured reports of prostate multiparametric MRI.

Lina Zhu1, Ge Gao1, Yi Liu1, Chao Han1, Jing Liu1, Xiaodong Zhang1, Xiaoying Wang2.   

Abstract

OBJECTIVES: To evaluate the feasibility of integrating computer-aided diagnosis (CAD) with structured reports of prostate multiparametric MRI (mpMRI).
METHODS: This retrospective study enrolled 153 patients who underwent prostate mpMRI for the purpose of targeted biopsy; patients were divided into a group with clinically significant prostate cancer (csPCa, Gleason score ≥ 3 + 4, n = 89) and a group with non-csPCa (n = 64). Ten inexperienced radiologists retrospectively evaluated these cases (single reader per case) twice using structured reports, and they were blinded to the pathologic results. Initially, the readers interpreted mpMRI without CAD. Six weeks later, they evaluated the same cases again with CAD assistance. At each time of image interpretation, lesions detected by the readers were marked on the prostate vector map in structured reports, and a PI-RADS score was given to each lesion. Diagnostic efficacy and reading time were evaluated for the two reading sessions.
RESULTS: With the assistance of CAD, the overall diagnostic efficacy was improved, i.e., the AUC increased from 0.83 to 0.89 (p = 0.018). Specifically, per-patient sensitivity (84.3% vs. 93.3%) and per-lesion sensitivity (76.7% vs. 88.8%) were significantly improved (all p < 0.05). Per-patient specificity with CAD (65.6%) was higher than that without CAD (56.3%), but statistical significance was not reached (p = 0.238). The reading time for each case decreased from 10.9 min to 7.8 min (p < 0.001).
CONCLUSIONS: It is feasible to integrate CAD with structured reports of prostate mpMRI. This reading paradigm can improve the diagnostic sensitivity of csPCa detection and reduce reading time among inexperienced radiologists.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computer-assisted diagnosis; Magnetic resonance imaging; Prostatic neoplasms; Structured reports

Mesh:

Substances:

Year:  2019        PMID: 31874336     DOI: 10.1016/j.clinimag.2019.12.010

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  6 in total

1.  Preoperative prediction of pelvic lymph nodes metastasis in prostate cancer using an ADC-based radiomics model: comparison with clinical nomograms and PI-RADS assessment.

Authors:  Xiang Liu; Xiangpeng Wang; Yaofeng Zhang; Zhaonan Sun; Xiaodong Zhang; Xiaoying Wang
Journal:  Abdom Radiol (NY)       Date:  2022-06-28

2.  Integrating patient symptoms, clinical readings, and radiologist feedback with computer-aided diagnosis system for detection of infectious pulmonary disease: a feasibility study.

Authors:  Tej Bahadur Chandra; Bikesh Kumar Singh; Deepak Jain
Journal:  Med Biol Eng Comput       Date:  2022-07-02       Impact factor: 3.079

3.  AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning.

Authors:  Pritesh Mehta; Michela Antonelli; Saurabh Singh; Natalia Grondecka; Edward W Johnston; Hashim U Ahmed; Mark Emberton; Shonit Punwani; Sébastien Ourselin
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 4.  Abbreviated MR Protocols in Prostate MRI.

Authors:  Andreas M Hötker; Hebert Alberto Vargas; Olivio F Donati
Journal:  Life (Basel)       Date:  2022-04-07

Review 5.  Artificial Intelligence Based Algorithms for Prostate Cancer Classification and Detection on Magnetic Resonance Imaging: A Narrative Review.

Authors:  Jasper J Twilt; Kicky G van Leeuwen; Henkjan J Huisman; Jurgen J Fütterer; Maarten de Rooij
Journal:  Diagnostics (Basel)       Date:  2021-05-26

Review 6.  Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly.

Authors:  Adam Retter; Fiona Gong; Tom Syer; Saurabh Singh; Sola Adeleke; Shonit Punwani
Journal:  Mol Oncol       Date:  2021-08-30       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.